Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322708 · ClinicalTrials.gov registry record · Phase 2
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
A Phase 2 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 2
- Development phase
- 277
- Enrollment target
NCT04322708 is a Phase 2 study that has completed, run by Allakos. The registered enrollment target is 277 participants.
The verdict
NCT04322708, a Phase 2 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 277 participants
- Enrollment target
Study Summary
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.
Interventions
- OTHER Placebo
- DRUG lirentelimab (AK002)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2022-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322708
The ClinicalTrials.gov registry entry for NCT04322708 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04322708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04322708 about?
NCT04322708 is a clinical study titled "A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis". This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo...
What is the current status of trial NCT04322708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2020-07-06. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04322708?
The interventions under investigation include: Placebo (OTHER), lirentelimab (AK002) (DRUG).
Who is sponsoring clinical trial NCT04322708?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.